Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04225260 · ClinicalTrials.gov registry record · Phase 3
Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines
A Phase 3 study, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 3
- Development phase
- 902
- Enrollment target
NCT04225260: Completed Phase 3 study, sponsored by Galderma R&D.
NCT04225260 is a Phase 3 study that has completed, run by Galderma R&D. The registered enrollment target is 902 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (17% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04225260, a Phase 3 study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 902 participants
- Enrollment target
Study Summary
This is a phase 3, multicenter, open-label study to evaluate the safety of QM1114-DP for the long term treatment of moderate to severe Glabellar (Frown) Lines (GL) and Lateral Canthal Lines (Crow's Feet and LCL).
Primary Outcome
4-point scale
Interventions
- BIOLOGICAL botulinum toxin neuromodulator
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 902 participants |
| Start Date | 2020-01-27 |
| Est. Completion | 2021-05-21 |
| Phase | Phase 3 |
What the finished NCT04225260 record still lists
NCT04225260 is an interventional study that assigns participants to a tested intervention. The registered 902 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (17% higher).
The record links to 0 conditions, and to 1 intervention - of which botulinum toxin neuromodulator is the first listed.
NCT04225260 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04225260 about?
NCT04225260 is a clinical study titled "Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines". This is a phase 3, multicenter, open-label study to evaluate the safety of QM1114-DP for the long term treatment of moderate to severe Glabellar (Frown) Lines (GL) and Lateral Canthal Lines (Crow's Feet and LCL).
What is the current status of trial NCT04225260?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 902 participants. The study started on 2020-01-27. Estimated completion is 2021-05-21.
What interventions are being tested in trial NCT04225260?
The interventions under investigation include: botulinum toxin neuromodulator (BIOLOGICAL).
Who is sponsoring clinical trial NCT04225260?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04225260's enrollment target sits among peer trials
902 349th of 2000 higher than 1,652 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05769777 · 901 participants · Phase 2
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
- NCT02352116 · 900 participants · NA
Evaluation of Post-PACU Pain Management in Pediatric Surgery
- NCT02414347 · 900 participants
F 18 T807 Tau PET Imaging of Alzheimer's Disease
- NCT02670408 · 900 participants
Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI